Intercept Pharmaceuticals shares are trading higher after HC Wainwright & Co upgraded the stock from Sell to Buy and raised its price target from $8 to $19.
Portfolio Pulse from Benzinga Newsdesk
Intercept Pharmaceuticals' stock has been upgraded from Sell to Buy by HC Wainwright & Co, with the price target raised from $8 to $19.
July 13, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intercept Pharmaceuticals' stock has been upgraded by HC Wainwright & Co, which could lead to a positive short-term impact on the stock price.
The upgrade from Sell to Buy by HC Wainwright & Co indicates a positive outlook for Intercept Pharmaceuticals. This, coupled with the raised price target, suggests an expectation of stock price increase, which could lead to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100